All DNA articles – Page 4
-
ArticleWomen in Stem with Dr Emily Leproust
This September edition of our Women in Stem series spotlights Dr Emily Leproust, CEO of Twist Bioscience. Dr Leproust began her STEM journey from a background in chemistry, eventually leading her to the forefront of DNA synthesis technology. She co-founded Twist Bioscience in 2013, now a thriving company reporting substantial ...
-
NewsEngineered immune cells for improved cancer defence
A collaborative team has uncovered a method to extend the functionality of CAR-T cells.
-
ArticleNew research holds significance in regulating T cell function
New research shows T cells use the nuclear receptor RARα not just for gene regulation, but also to trigger cell surface events that activate them against pathogens and cancer.
-
NewsMultiomics approach unveils flu severity insights
Some individuals may experience more severe symptoms when infected with the same virus compared to others. The reasons behind this variability are not yet fully understood. While viral factors, such as differences in the virus strain, do play a role, they cannot account for the diverse responses observed among individuals ...
-
NewsImmunotherapy: antibody set for combating tumours
A recent study sheds light on the potential of artificial DNA structures that, when combined with antibodies, guide the immune system to target cancer cells specifically.
-
NewsDNA repair breakthroughs for innovative cancer treatment
This study explores cell survival, the continuous repair of DNA breaks is crucial. Failure to repair DNA effectively can result in mutations, contributing to the development of cancer.
-
ArticlePrecision medicine: exploring the impact of DNA Testing
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
-
NewsA structural insight into HIV drug-resistance mechanisms
New Salk Institute, US, research could lead to the development of new HIV therapeutics that overcome resistance to existing drugs.
-
ArticleNavigating the challenges and opportunities of AI in drug development and personalised medicine
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
-
News
Rare cause of hereditary cancer missed in younger patients
US investigators find that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
-
NewsGut bacteria linked to fatty deposits in heart arteries
Swedish study reveals a significant link between specific gut bacteria and the development of coronary atherosclerotic plaques, a leading cause of heart attacks.
-
ArticleEpigenetic editing: the next generation of genetic medicine
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
-
NewsResearchers develop tool that could improve liquid biopsy
A US study has overcome a major obstacle in cell-free DNA (cfDNA) testing or liquid biopsy, offering promising advancements in disease diagnosis and monitoring.
-
NewsNew biomarker identified for major depressive disorder
Local gyrification index, which measures cortical folding in the brain, could be a novel neuroimaging marker for major depressive disorder.
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
-
ArticleKey considerations before commencing cell line development
Cell line development (CLD) is a critical, early step when entering the development phase of a biotherapeutic. Access to specialist skills and experience, either in-house or remotely, and to multiple technologies and equipment can prove invaluable for the timely and successful completion of this stage. Here, Dr Alison Porter addresses ...
-
NewsDNA technology helps slow down and scan molecules multiple times
Swiss researchers have achieved near-perfect control over the manipulation of individual DNA molecules, allowing them to be identified and characterised with unprecedented precision
-
NewsNew tool reveals hidden complexity of genome architecture
A German team of scientists have developed a technique known as Genome Architecture Mapping that allows them to study complex genome interactions.
-
ArticleGame-changing pan-TEAD inhibitor for solid tumours
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
-
News$6 Million grant issued to Penn Medicine to investigate role of DNA in cardiac cell development
Penn Medicine researchers are interested in how cardiac cells use DNA to establish and maintain their specification.